Allogene Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on August 12, 2026, covering the three and six months ended June 30, 2026, disclosing a net loss of $42.677 million for the second quarter and reporting its first collaboration revenue alongside a significant equity raise.

Key Highlights

  • Q2 2026 net loss: $42.677 million, compared to $50.943 million in Q2 2025, according to the filing.
  • First collaboration revenue recorded: $4.640 million in collaboration revenue from a related party for both the three and six months ended June 30, 2026, versus $0 in the same periods of 2025.
  • Public offering completed in Q2: 100,200,000 shares of common stock were issued, raising net proceeds of $187.872 million after commissions and offering costs of $12.5 million.
  • Total stockholders' equity increased: From $292.542 million at December 31, 2025, to $436.175 million at June 30, 2026.
  • Accumulated deficit: $2.095993 billion as of June 30, 2026, up from $2.010709 billion at December 31, 2025.
  • Shares outstanding: 345,490,881 shares of common stock as of August 10, 2026, as reported in the filing.
  • Total assets: $550.091 million at June 30, 2026, compared to $415.905 million at December 31, 2025.

Allogene Therapeutics Q2 2026: Reduced Net Loss, New Revenue, and Major Equity Raise

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company based in South San Francisco, California, reported a net loss of $42.677 million for the three months ended June 30, 2026, according to its 10-Q filing. This compares to a net loss of $50.943 million for the same period in 2025. For the six months ended June 30, 2026, the company reported a net loss of $85.284 million, down from $110.676 million in the first half of 2025. Net loss per share, basic and diluted, was $(0.13) for Q2 2026 and $(0.30) for the first half of 2026, compared to $(0.23) and $(0.51) in the respective prior-year periods.

The company disclosed $4.640 million in collaboration revenue from a related party for both the second quarter and the first half of 2026, the first such revenue recorded in these periods. Total operating expenses for Q2 2026 were $51.560 million, with research and development expenses of $30.721 million and general and administrative expenses of $20.839 million. This compared to total operating expenses of $56.819 million in Q2 2025, which also included $2.382 million in impairment of long-lived assets not present in the 2026 period.

During the second quarter, the company completed a public offering of 100,200,000 shares of common stock, generating net proceeds of $187.872 million after commissions and offering costs of $12.5 million. Additionally, in Q1 2026, the company raised $20.668 million through its at-the-market offering, net of costs of $0.3 million. As of June 30, 2026, total assets were $550.091 million, including cash and cash equivalents of $38.626 million and short-term and long-term investments totaling $384.964 million. The authorized share count was increased to 800,000,000 shares from 400,000,000 shares during the period, as the filing noted.

What Was Disclosed

Allogene Therapeutics filed its 10-Q for the quarter ended June 30, 2026, reporting reduced net losses year over year, the company's first collaboration revenue from a related party, a major public equity offering, and a substantial increase in total assets and stockholders' equity.